Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TQB2916 plus gemcitabine and nab-paclitaxel as first-line treatment for metastatic pancreatic cancer
CTR20244797Phase 2Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2916 in pancreatic cancer (PC), pancreatic adenocarcinoma (PDAC), sponsored by Nanjing Shunxin Pharmaceutical. Started Apr 2025; status: active.
02
Drugs
TQB2916
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20244797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244797.